Shares of NewLink Genetics Corp. (NASDAQ:NLNK) have been given an average rating of “Hold” by the eight brokerages that are currently covering the firm. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $25.80.

A number of analysts have recently commented on the company. Zacks Investment Research upgraded NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, July 26th. Jefferies Group restated a “hold” rating and issued a $12.00 target price (up previously from $10.00) on shares of NewLink Genetics Corp. in a research note on Friday, October 28th.

NewLink Genetics Corp. (NASDAQ:NLNK) opened at 13.56 on Thursday. NewLink Genetics Corp. has a 12-month low of $9.23 and a 12-month high of $38.92. The firm’s 50-day moving average price is $13.68 and its 200 day moving average price is $11.92. The stock’s market cap is $394.47 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last posted its quarterly earnings results on Tuesday, November 1st. The company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.06. The business had revenue of $15.35 million for the quarter, compared to the consensus estimate of $3.83 million. NewLink Genetics Corp. had a negative return on equity of 56.48% and a negative net margin of 303.49%. Analysts anticipate that NewLink Genetics Corp. will post ($3.06) EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in NLNK. BlackRock Fund Advisors boosted its position in NewLink Genetics Corp. by 8.5% in the first quarter. BlackRock Fund Advisors now owns 1,185,912 shares of the company’s stock worth $21,584,000 after buying an additional 92,818 shares during the last quarter. Renaissance Technologies LLC boosted its position in NewLink Genetics Corp. by 1,176.7% in the first quarter. Renaissance Technologies LLC now owns 726,700 shares of the company’s stock worth $13,226,000 after buying an additional 669,779 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in NewLink Genetics Corp. by 1.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 526,762 shares of the company’s stock worth $7,912,000 after buying an additional 9,806 shares during the last quarter. Northern Trust Corp boosted its position in NewLink Genetics Corp. by 1.1% in the third quarter. Northern Trust Corp now owns 272,613 shares of the company’s stock worth $4,094,000 after buying an additional 3,051 shares during the last quarter. Finally, Teachers Advisors Inc. boosted its position in NewLink Genetics Corp. by 1.5% in the second quarter. Teachers Advisors Inc. now owns 196,307 shares of the company’s stock worth $2,210,000 after buying an additional 2,971 shares during the last quarter. 50.07% of the stock is owned by institutional investors.

About NewLink Genetics Corp.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

5 Day Chart for NASDAQ:NLNK

Receive News & Stock Ratings for NewLink Genetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp. and related stocks with our FREE daily email newsletter.